Skip to main content
TipRanks
Go Ultimate75% OFF

Syros Pharmaceuticals (0LC7) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Syros Pharmaceuticals has a market cap or net worth of $2,683.00. The enterprise value is $86.52M.

Market Cap
$2,683.00
Enterprise Value
$86.52M

Share Statistics

Syros Pharmaceuticals has 26,832,457 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
26,832,457
Owned by Insiders
―
Owned by Institutions
0.53%

Financial Efficiency

Syros Pharmaceuticals’s return on equity (ROE) is -9.88 and return on invested capital (ROIC) is -91.82%.

Return on Equity (ROE)
-9.88
Return on Assets (ROA)
-0.98
Return on Invested Capital (ROIC)
-91.82%
Return on Capital Employed (ROCE)
-0.98
Revenue Per Employee
146.12K
Profits Per Employee
-2.42M
Employee Count
68
Asset Turnover
0.06
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Syros Pharmaceuticals is -0.00. Syros Pharmaceuticals’s PEG ratio is 0.00.

PE Ratio
-0.00
PS Ratio
0.00
PB Ratio
0.00
Price to FCF
-0.00
Price to Operating Cash Flow
-0.00
PEG Ratio
0.00

Income Statement

In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.

Revenue
9.94M
Gross Profit
7.68M
Operating Income
-128.99M
Pretax Income
-164.57M
Net Income
-164.57M
EBITDA
-157.19M
Earnings Per Share (EPS)
-5.81

Cash Flow

In the last 12 months, operating cash flow was -100.02M and capital expenditures -38,000, giving a free cash flow of -100.06M billion.

Operating Cash Flow
-100.02M
Free Cash Flow
-100.06M
Free Cash Flow per Share
-3.88

Dividends & Yields

Syros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-4099105.48%
Earnings Yield
-5810043.21%

Stock Price Statistics

Beta
68.42
52-Week Price Change
-96.09%
50-Day Moving Average
0.02
200-Day Moving Average
0.09
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Syros Pharmaceuticals upcoming earnings date is ―, TBA (Not Confirmed).

Last Earnings Date
Nov 18, 2025
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

Syros Pharmaceuticals as a current ratio of 3.95, with Debt / Equity ratio of 372.55%

Current Ratio
3.95
Quick Ratio
3.95
Debt to Market Cap
0.19
Net Debt to EBITDA
0.49
Interest Coverage Ratio
-25.16

Taxes

In the past 12 months, Syros Pharmaceuticals has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Syros Pharmaceuticals EV to EBITDA ratio is 0.49, with an EV/FCF ratio of 0.70.

EV to Sales
-7.79
EV to EBITDA
0.49
EV to Free Cash Flow
0.70
EV to Operating Cash Flow
0.71

Balance Sheet

Syros Pharmaceuticals has $58.27M in cash and marketable securities with $60.23M in debt, giving a net cash position of -$1.95M billion.

Cash & Marketable Securities
$58.27M
Total Debt
$60.23M
Net Cash
-$1.95M
Net Cash Per Share
-$0.07
Tangible Book Value Per Share
-$0.28

Margins

Gross margin is 77.33%, with operating margin of -1298.19%, and net profit margin of -1656.34%.

Gross Margin
77.33%
Operating Margin
-1298.19%
Pretax Margin
-1656.34%
Net Profit Margin
-1656.34%
EBITDA Margin
-1582.08%
EBIT Margin
-1604.74%